Description
ERLOTINIB (Taro) 150 mg is indicated as first-line therapy in EGFR mutation-positive NSCLC. It interferes with tumor cell proliferation and survival by inhibiting EGFR tyrosine kinase activity.
EGFR inhibitor for advanced lung cancer
ERLOTINIB (Taro) 150 mg is indicated as first-line therapy in EGFR mutation-positive NSCLC. It interferes with tumor cell proliferation and survival by inhibiting EGFR tyrosine kinase activity.
Reviews
There are no reviews yet.